A conflict of interest in healthcare exists when a doctor, researcher, or institution has a secondary interest, usually financial, that could compromise their professional judgment about patient care. The conflict doesn’t mean someone has actually done something wrong. It means the conditions exist for bias to creep in, even unconsciously, because a personal benefit competes with the obligation to put patients first.
These conflicts are widespread in medicine. They show up in how drugs get prescribed, how research gets funded, how hospitals make purchasing decisions, and how individual doctors choose between treatment options. Understanding them helps you evaluate the care and medical information you receive.
Financial vs. Nonfinancial Conflicts
Conflicts of interest in healthcare fall into two broad categories: financial and nonfinancial.
Financial conflicts involve anything with monetary value. That includes direct payments from pharmaceutical or medical device companies, stock ownership in a company whose products a doctor prescribes, consulting fees, paid speaking engagements, and royalties on patented devices or procedures. It also includes how physicians are paid for their services. A doctor paid per procedure, for instance, has a financial incentive to recommend more procedures, whether or not a patient truly needs them.
Nonfinancial conflicts are harder to spot but just as real. These include personal relationships, familial ties, academic rivalries, intellectual commitments to a particular theory, and the desire for professional advancement. A researcher deeply invested in a hypothesis may unconsciously interpret data in ways that support it. A physician who trained under a particular mentor may favor that mentor’s preferred treatment approach long after better options emerge. Nepotism, where hiring or referral decisions favor friends or family members, is another common form.
How Industry Payments Affect Prescribing
The relationship between pharmaceutical companies and physicians is one of the most studied conflicts in healthcare. Companies pay doctors to consult, give talks, attend conferences, and participate in advisory boards. These payments are legal, but they come with measurable consequences.
Nearly every published study examining the relationship has found the same thing: physicians who receive industry payments prescribe differently than those who don’t. The pattern is consistent. Doctors who accept payments tend to prescribe more brand-name drugs over generics, favor medications made by the paying company, adopt new drugs more quickly (before long-term safety data is available), and prescribe more expensive treatments when cheaper alternatives exist. These shifts increase drug costs for patients and the healthcare system without necessarily improving outcomes.
The influence doesn’t require large sums. Even small gifts, free meals, and drug samples have been shown to shift prescribing patterns. The effect operates below conscious awareness for most physicians, which is part of what makes it so persistent. Few doctors believe they are personally influenced by industry relationships, yet the aggregate data tells a different story.
Conflicts in Medical Research
When a company funds a clinical trial for its own product, a structural conflict exists from the start. The funder benefits financially if the trial produces favorable results. This doesn’t mean every industry-funded study is unreliable, but the incentive structure creates opportunities for bias at every stage: which questions get asked, how trials are designed, which outcomes get measured, and which results get published.
One of the challenges in quantifying this bias is that independent funding for clinical trials is vanishingly rare. An analysis of high-quality pain and migraine trials found that out of 176 studies, only two were funded by nonprofit sources, and 31 didn’t disclose their funding at all. When nearly all the evidence base comes from industry-funded work, there’s often no independent comparison point.
Medical journals have responded by requiring authors to disclose their financial ties. The International Committee of Medical Journal Editors requires every author to report all relationships that might bias their work, including employment, consulting fees, stock ownership, honoraria, patents, and paid expert testimony. The committee also requires disclosure of nonfinancial conflicts like personal relationships, academic competition, and intellectual beliefs that could introduce bias. These disclosures don’t eliminate conflicts, but they let readers evaluate research with full context.
Institutional Conflicts
Conflicts of interest don’t only affect individuals. Hospitals, medical schools, professional societies, and research institutions can have their own conflicting financial relationships with industry. A professional society that receives funding from a drug company through educational grants, conference sponsorships, or journal advertisements may face pressure, subtle or otherwise, when developing clinical practice guidelines that affect that company’s products.
Hospitals that own diagnostic imaging centers or surgical facilities have a financial incentive to refer patients to those facilities. Research institutions that hold patents on medical devices or drugs face conflicts when their own faculty study those products. These institutional-level conflicts can be even more consequential than individual ones because they shape policies and guidelines that affect thousands of patients.
How Conflicts Are Managed
The standard approach to managing conflicts of interest in healthcare relies on three strategies: disclosure, recusal, and oversight.
Disclosure is the most common requirement. Federal regulations require that members of institutional review boards, the committees that approve human research studies, cannot vote on any protocol in which they have a conflicting interest. In practice, a national survey found that 100% of review board chairs reported that members with conflicts never voted on the relevant protocols. About 63% said conflicted members also left the room during discussion of those protocols, though the rest allowed them to stay and provide information.
Beyond individual recusal, about three-quarters of research review boards have a defined process for members to disclose industry relationships, and two-thirds require voting members to report those relationships. Roughly half of board chairs believe that oversight of member conflicts should fall to a separate body within the institution, such as a dedicated conflict of interest committee or a senior administrator, rather than being handled internally by the board itself.
These safeguards help, but they’re imperfect. Disclosure alone doesn’t remove the conflict. It shifts the burden to patients, readers, or committee members to decide how much weight to give the disclosed relationship.
What Patients See When Conflicts Are Disclosed
Since 2013, the Open Payments program run by the Centers for Medicare and Medicaid Services has made industry payments to doctors publicly searchable. Drug and device companies must report payments in three categories: general payments (meals, travel, consulting fees, speaking fees), research-related payments, and ownership or investment interests like stock holdings. For the 2026 reporting year, any individual payment of $13.82 or more must be reported, as well as any total exceeding $138.13 per year from a single company.
You can look up your own doctor at openpaymentsdata.cms.gov. The search tool covers physicians, physician assistants, advanced practice nurses, and teaching hospitals. You can also search by company to see which providers received payments.
Disclosure does affect how patients view their doctors, but in specific ways. A randomized experiment published in the Journal of General Internal Medicine found that patients rated physicians who received more than $13,000 in industry payments significantly lower on honesty and fidelity compared to doctors with no payments. Among patients who actually looked up their own physician on the Open Payments site, trust in honesty and fidelity dropped as the payment amount increased. Notably, disclosure did not change how patients rated their doctor’s competence, and it had no effect on trust in the medical profession overall or in the pharmaceutical industry as a whole. The concern, in other words, is personal: patients worry about whether their specific doctor’s advice is influenced by money, not whether medicine in general is compromised.
Why Conflicts Persist
Eliminating conflicts of interest entirely from healthcare would require severing financial relationships that also serve legitimate purposes. Industry funding supports the majority of clinical trials. Physician consultants help companies design better products. Continuing medical education often depends on industry sponsorship. The challenge is managing these relationships so they don’t override the professional obligation to put patients first.
The core tension was articulated well in a National Academies report: professionals are granted significant privileges, including the power to set their own educational and ethical standards, in return for maintaining competence and acting in patients’ interests. But the power to set those standards creates a situation where ethical goals can become mixed with protection of self-interest and privilege. What distinguishes a true profession from other occupations is the willingness to set aside personal gain when it conflicts with the people being served.